The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 06, 2026

Filed:

Jul. 08, 2025
Applicant:

Hangzhou Tianlong Pharmaceutical Co., Ltd., Hangzhou, CN;

Inventors:

Zeao Huang, Hangzhou, CN;

Gengshen Song, Hangzhou, CN;

Shuo Yang, Hangzhou, CN;

Yang Yang, Hangzhou, CN;

Zhikang Tian, Hangzhou, CN;

Yucheng Wu, Hangzhou, CN;

Kai Xiong, Hangzhou, CN;

Zhongcai Gao, Hangzhou, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); A61K 9/1272 (2025.01); A61K 9/51 (2006.01); A61K 31/712 (2006.01); A61K 31/7125 (2006.01); A61K 31/713 (2006.01); A61K 47/02 (2006.01); A61P 31/20 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12N 15/1131 (2013.01); A61K 9/1272 (2013.01); A61K 9/5123 (2013.01); A61K 31/712 (2013.01); A61K 31/7125 (2013.01); A61K 31/713 (2013.01); A61K 47/02 (2013.01); A61P 31/20 (2018.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/312 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/351 (2013.01);
Abstract

The present disclosure provides a double-stranded RNAi agent for targeting and regulating HBV gene expression and a use thereof. The double-stranded RNAi agent comprises an antisense strand and a sense strand complementary to the antisense strand forming a duplex region. The nucleotide sequence of the antisense strand is as shown in SEQ ID NO: 8, 11, or 13, or the nucleotide sequence of the antisense strand is a modified sequence of the sequence shown in SEQ ID NO: 8, 11, or 13. Results from cell and animal experiments demonstrate that the double-stranded RNAi agent provided in the present disclosure can significantly reduce the expression of one or more HBV genes, block the viral life cycle, and can be used to develop drugs for treating diseases related to HBV gene expression.


Find Patent Forward Citations

Loading…